Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.37 USD | +0.74% | -1.44% | +10.48% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.48% | 287M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.66% | 22.2B | |
-16.53% | 21.23B | |
-8.96% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics : Submits New Drug Application to FDA For Vadadustat For Anemia Due to Chronic Kidney Disease